Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference, scheduled for January 13-16, 2025, in San Francisco, will be attended by Tevogen's Founder and CEO Ryan Saadi, MD, MPH.
The company, which specializes in developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, will be part of what is recognized as the industry's largest and most informative healthcare investment symposium. The event brings together key stakeholders to discuss healthcare innovations and advancements.
Tevogen Bio (Nasdaq: TVGN), una società biotech specializzata in immunoterapia in fase clinica, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. La conferenza, in programma dal 13 al 16 gennaio 2025 a San Francisco, vedrà la partecipazione del Fondatore e CEO di Tevogen, Ryan Saadi, MD, MPH.
L'azienda, che si concentra nello sviluppo di terapeutiche a base di cellule T geneticamente non modificate e pronte all'uso per malattie infettive e tumori, sarà presente a quello che è riconosciuto come il più grande e informativo simposio di investimenti nel settore sanitario. L'evento riunisce i principali stakeholder per discutere delle innovazioni e dei progressi nel campo della sanità.
Tevogen Bio (Nasdaq: TVGN), una compañía biotecnológica especializada en inmunoterapia en etapa clínica, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan. La conferencia, programada del 13 al 16 de enero de 2025 en San Francisco, contará con la presencia del Fundador y CEO de Tevogen, Ryan Saadi, MD, MPH.
La empresa, que se especializa en desarrollar terapéuticas de células T genéticamente no modificadas y listas para usar para enfermedades infecciosas y cánceres, formará parte de lo que es reconocido como el simposio de inversión en salud más grande e informativo de la industria. El evento reúne a los principales actores para discutir innovaciones y avances en la salud.
Tevogen Bio (Nasdaq: TVGN), 임상 단계의 전문 면역 요법 생명공학 회사가 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 컨퍼런스는 2025년 1월 13일부터 16일까지 샌프란시스코에서 열리며, Tevogen의 창립자이자 CEO인 Ryan Saadi, MD, MPH가 참석할 예정입니다.
감염병 및 암을 위해 사용할 수 있는 유전자 수정이 없는 T 세포 치료제를 개발하는 데 특화된 이 회사는 산업에서 가장 크고 정보가 풍부한 헬스케어 투자 심포지엄의 일원이 될 것입니다. 이 행사는 주요 이해관계자들이 모여 헬스케어 혁신 및 발전에 대해 논의하는 자리입니다.
Tevogen Bio (Nasdaq: TVGN), une entreprise biotechnologique spécialisée dans l'immunothérapie en phase clinique, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. La conférence, prévue du 13 au 16 janvier 2025 à San Francisco, sera marquée par la présence du Fondateur et PDG de Tevogen, Ryan Saadi, MD, MPH.
L'entreprise, qui se spécialise dans le développement de thérapeutiques à base de cellules T génétiquement non modifiées et prêtes à l'emploi pour les maladies infectieuses et les cancers, fera partie de ce qui est reconnu comme le plus grand et le plus informatif symposium d'investissement dans le secteur de la santé. L'événement réunit les principaux acteurs pour discuter des innovations et des avancées dans le domaine de la santé.
Tevogen Bio (Nasdaq: TVGN), ein klinisch tätiges Spezialbiotech-Unternehmen im Bereich Immuntherapie, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. Die Konferenz, die vom 13. bis 16. Januar 2025 in San Francisco stattfindet, wird von Tevogen's Gründer und CEO Ryan Saadi, MD, MPH, besucht.
Das Unternehmen, das sich auf die Entwicklung von sofort einsatzbereiten, genetisch nicht modifizierten T-Zell-Therapeutika gegen Infektionskrankheiten und Krebserkrankungen spezialisiert hat, wird Teil des größten und informativsten Symposions für Investitionen im Gesundheitswesen sein, das in der Branche anerkannt ist. Die Veranstaltung bringt wichtige Interessengruppen zusammen, um über Innovationen und Fortschritte im Gesundheitswesen zu diskutieren.
- None.
- None.
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be attending the J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.
The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together key stakeholders to discuss innovations and advancements in the sector.
For inquiries about Tevogen Bio’s JP Morgan events, please contact Communications at communications@tevogen.com
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
When is Tevogen Bio (TVGNW) attending the J.P. Morgan Healthcare Conference 2025?
What type of therapeutics is Tevogen Bio (TVGNW) developing?
Where will the 43rd J.P. Morgan Healthcare Conference that Tevogen Bio (TVGNW) is attending be held?
Who will represent Tevogen Bio (TVGNW) at the 2025 J.P. Morgan Healthcare Conference?
